van Bodegom D, Zhong J, et al. Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Blood. 2012;120:2853-63.
http://www.ncbi.nlm.nih.gov/pubmed/22915648
Ott CJ, Kopp N, Bird L, et al. BET bromodomain inhibition targets both c-MYC and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120:2843-52.
http://www.ncbi.nlm.nih.gov/pubmed/22904298
Shindoh N, Yoda A, Yoda Y, et al. Next-generation cDNA screening for oncogene and resistance phenotypes. PLoS One 2012;7:e49201.
http://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0049201
Weigert O, Weinstock DM. The evolving contribution of hematopoietic progenitors to lymphomagenesis. Blood. 2012 Sep 27;120(13):2553-61.
http://www.ncbi.nlm.nih.gov/pubmed/22869790
Weigert O, Lane AA, Bird L, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012;209(2):259-73.
http://www.ncbi.nlm.nih.gov/pubmed/22271575
Dutta C, Day T, Kopp N, et al. BCL2 suppresses PARP1 function and nonapoptotic cell death. Canc Res 2012;72:4193-203.
http://www.ncbi.nlm.nih.gov/pubmed/22689920
Weigert O, Kopp N, Lane AA, et al. Molecular ontogeny of donor-derived follicular lymphomas. Cancer Discovery 2012;2(1):47-55.
http://cancerdiscovery.aacrjournals.org/content/2/1/47.full
Zhong J, Kim MS, Chaerkady R, et al. TSLP signaling network revealed by SILAC-based phosphoproteomics. Mol Cell Proteomics. 2012 Feb 16. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22345495